Lophius Biosciences is a biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.
The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation and Reverse T Cell Technology platforms. Whereas the T-activation technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.
With its T-Track CMV leading product, based on T-activation technology, Lophius offers a sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.
Lophius Biosciences was founded in 2002 and is headquartered in Regensburg, DE
Report incorrect company information
Lophius Biosciences Office Locations
Lophius Biosciences has an office in Regensburg
Regensburg, DE (HQ)
13 Am Biopark
Report incorrect company information
Lophius Biosciences Financials and Metrics
Summary Metrics
Founding Date | 2002 |
Total Funding | $14.4 m |
Latest funding size | $2.36 m |
Time since last funding | a year ago |
Investors | VRD GmbH, Bayern Kapital, wolf biotech gmbh, WIC, Heidelberg Innovation, BACH Wirtschafts-Consulting, Bavarian Growth Fund, S-Refit |
Lophius Biosciences's latest funding round in March 2017 was reported to be $2.4 m. In total, Lophius Biosciences has raised $14.4 m
Report incorrect company information
